Creative Medical Technology (NASDAQ:CELZ) Issues Quarterly Earnings Results

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings results on Friday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.01, Zacks reports.

Creative Medical Technology Stock Up 0.9%

Shares of NASDAQ CELZ traded up $0.02 during midday trading on Friday, reaching $2.31. The company had a trading volume of 68,109 shares, compared to its average volume of 69,840. The stock has a market cap of $8.54 million, a PE ratio of -0.89 and a beta of 1.87. Creative Medical Technology has a one year low of $1.50 and a one year high of $6.25. The firm’s fifty day moving average price is $2.05 and its 200-day moving average price is $2.32.

Hedge Funds Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission (SEC). 1.42% of the stock is owned by institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.